SX
Therapeutic Areas
Neurophth Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NFS-01 (NR082/rAAV2-ND4) | Leber's Hereditary Optic Neuropathy (LHON) due to ND4 mutation | Phase 3 |
| NFS-02 (rAAV2-ND1) | Leber's Hereditary Optic Neuropathy (LHON) due to ND1 mutation | Phase 1/2 |
| Pipeline Candidates | Dominant Optic Atrophy, Optic Nerve Injury, Vascular Retinopathies | Preclinical |